If you opened Google Scholar or picked up the latest issues of Nature Neuroscience or The Lancet Neurology over the past few days, you would spot two huge themes: how our sleep architecture betrays early brain changes, and how combining blood tests with genetics creates an exact clock for when symptoms will start.

For decades, medicine treated dementia as an unyielding natural consequence of aging. But between the massive trial pipeline data released this week, new lipid discoveries from UT Health, and a surge in repurposing existing cardiovascular medications, the paradigm has officially shifted from late-stage symptom management to early multi-target prevention.

Explore how Glassbury AI uses Google Cloud, MedGemma, and Vertex AI Explainable AI to guarantee FDA Diversity Action Plan compliance and accelerate Alzheimer's clinical trial matching.